A Utah Court failed to uphold a motion by Myriad Genetics that would have stopped its rival Ambry Genetics from offering a diagnostic test for the BRCA1 and BRCA2 genes. Myriad had claimed that Ambry was infringing some of its patents in offering the test. The court denied this preliminary injunction so Ambry is free to test while this case is further settled. Myriad is still pursuing a trial to bring this issue to closure. In the meantime, Myriad's stock fell 12% on the news. I don't think this ends Myriads case by any means but it suggests the facts at issue might not be as big a slam dunk as the company often tries to portray. See Reuters or Bloomberg.
Posted by Bruce Lehr Mar 11th 2014.